BIOLIFE SOLUTIONS INC

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

BLFS$38.61+3.5%Stored close · as of Oct 5, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,
(In thousands, except per share and share data)	2024	2023
Assets
Current assets:
Cash and cash equivalents	$95,386	$27,896
Available-for-sale securities, current portion	9,198	16,288
Accounts receivable, trade, net of allowance for credit losses of $153 and $1,603 as of December 31, 2024 and December 31, 2023, respectively	9,168	7,898
Inventories	29,013	27,164
Prepaid expenses and other current assets	5,996	4,667
Current assets, discontinued operations	—	36,691
Total current assets	148,761	120,604
Assets held for rent, net	6,103	6,917
Property and equipment, net	6,084	5,689
Operating lease right-of-use assets, net	10,674	6,878
Long-term deposits and other assets	379	71
Available-for-sale securities, long term	4,628	548
Equity Investments	995	5,069
Intangible assets, net	9,559	11,996
Goodwill	212,304	212,304
Long-term assets, discontinued operations	—	42,638
Total assets	$399,487	$412,714
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$3,573	$2,270
Accrued expenses and other current liabilities	12,451	9,121
Sales taxes payable	4,256	4,400
Lease liabilities, operating, current portion	1,511	1,286
Debt, current portion	10,943	6,285
Current liabilities, discontinued operations	—	18,816
Total current liabilities	32,734	42,178
Lease liabilities, operating, long-term	12,723	8,695
Debt, long-term	4,997	17,561
Deferred tax liabilities	124	114
Long-term liabilities, discontinued operations	—	6,503
Total liabilities	50,578	75,051
Commitments and contingencies (Note 12)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023	—	—

Common stock, $0.001 par value; 150,000,000 shares authorized, 46,906,765 and 45,167,225 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	47	45
Additional paid-in capital	683,939	652,880
Accumulated other comprehensive loss, net of taxes	24	(345)
Accumulated deficit	(335,101)	(314,917)
Total shareholders’ equity	348,909	337,663
Total liabilities and shareholders’ equity	$399,487	$412,714

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.